Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $41.50 USD
Change Today 0.00 / 0.00%
Volume 410.9K
WX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

wuxi pharmatech cayman-adr (WX) Snapshot

Open
$41.72
Previous Close
$41.50
Day High
$41.89
Day Low
$41.03
52 Week High
05/14/15 - $46.14
52 Week Low
08/4/14 - $31.24
Market Cap
3.0B
Average Volume 10 Days
392.4K
EPS TTM
$1.41
Shares Outstanding
71.5M
EX-Date
--
P/E TM
29.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for WUXI PHARMATECH CAYMAN-ADR (WX)

wuxi pharmatech cayman-adr (WX) Related Businessweek News

No Related Businessweek News Found

wuxi pharmatech cayman-adr (WX) Details

Wuxi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development services company in China and the United States. It operates through two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical, genomics, bioinformatics, research reagent production, and clinical services; services for discovery and development of biologics; and laboratory services, including testing services for biologics, medical devices, and combination products, as well as production of cell therapies. The Manufacturing Services segment provides manufacturing services, including development of manufacturing processes; and the production of advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products, and in commercial products, as well as the production of biologic products. The company sells its products to pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and non-profit organizations. Wuxi PharmaTech (Cayman) Inc. was founded in 2000 and is headquartered in Shanghai, China.

8,837 Employees
Last Reported Date: 04/15/15
Founded in 2000

wuxi pharmatech cayman-adr (WX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

wuxi pharmatech cayman-adr (WX) Key Developments

WuXi PharmaTech Plans $250 Million Health-Care Fund

WuXi PharmaTech (Cayman) Inc. (NYSE:WX) is looking to set up a new venture capital fund focusing on health-care companies in China and the U.S. The fund aims to raise up to $250 million, according to an SEC filing. WuXi spokesperson Hui Cai declined to comment on the fund.

University of Pennsylvania Signs strategic manufacturing collaboration with WuXi AppTec

WuXi AppTec (China) has signed a strategic manufacturing collaboration with the University of Pennsylvania's (US) Gene Therapy Program. Under the agreement, university scientists will work with WuXi to set up processes to manufacture viral vectors at the company's production plant in Philadelphia. The collaboration builds on WuXi's existing partnerships with academic institutions, following closely on a genomics-focused tie-up with China's Fudan University earlier this month. The collaboration with the University of Pennsylvania is expected to expand WuXi's manufacturing of adeno-associated virus (AAV) vectors - which can be used in gene therapy - by leveraging the university's expertise in viral vector production and boosting the company's overseas research and development capabilities.

WuXi PharmaTech (Cayman) Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for the Second Quarter of 2015; Revises Financial Guidance for the Full Year 2015

WuXi PharmaTech (Cayman) Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2015. For the quarter, total net revenues were $180,045,000 against $146,716,000 a year ago. Operating income was $16,992,000 against $23,411,000 a year ago, due to increased selling and marketing expenses, higher general and administrative expenses including compensation cost of management due to business expansion, and increased research and development expenses in biologics, discovery biology, genomics, and other areas, partially offset by the 17.1% increase in gross profit. Income before income taxes was $22,032,000 against $21,687,000 a year ago. Net income was $17,786,000 or $0.25 per diluted ADS against $17,819,000 or $0.24 per diluted ADS a year ago, mainly due to the 27.4% year-over-year decrease in operating income, an adverse change in realized gains on settled foreign-exchange forward contracts (losses of $0.2 million in the first quarter of 2015 compared to gains of $1.8 million in the first quarter of 2014), larger equity-method investment losses from joint ventures with PRA and MedImmune and other equity-method investments, and lower gains on the sale of investments by the corporate venture fund (gains of $2.6 million in the first quarter of 2015 compared to gains of $5.0 million in the first quarter of 2014), partially offset by a favorable change of $15.0 million in mark-to-market gains and losses on foreign-exchange forward contracts (gains of $1.1 million in the first quarter of 2015 compared to losses of $13.9 million in the first quarter of 2014). Non-GAAP operating income was $25,274,000 against $27,872,000 a year ago, due to increased selling and marketing expenses, higher general and administrative expenses including compensation cost of management due to business expansion, and increased research and development expenses in biologics, discovery biology, genomics, and other areas, partially offset by the 20.2% increase in non-GAAP gross profit. Non-GAAP net income was $25,622,000 or $0.36 per diluted ADS against $22,263,000 or $0.30 per diluted ADS a year ago. Operating cash flow was $35.3 million and capital expenditures was $38.7 million in the quarter. The company provided earnings guidance for the second quarter of 2015. The company expects total net revenues of $194 million to $196 million; GAAP diluted earnings per ADS of $0.25-$0.27; Non-GAAP diluted earnings per ADS of $0.38-$0.40. The company revised financial guidance for the full-year 2015. The company expects total net revenues of $790 million to $800 million, the same as previous guidance; GAAP diluted earnings per ADS of $1.21 to $1.26, compared to previous guidance of $1.31 to $1.36; Non-GAAP diluted earnings per ADS of $1.73 to $1.78, the same as previous guidance; Capital expenditures of $180 million to $200 million, the same as previous guidance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WX:US $41.50 USD 0.00

WX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $77.62 USD +3.18
Ergomed PLC 180.00 GBp 0.00
Hangzhou Tigermed Consulting Co Ltd CNY34.02 CNY -1.64
ICON PLC $80.80 USD -0.06
PAREXEL International Corp $68.96 USD +0.28
View Industry Companies
 

Industry Analysis

WX

Industry Average

Valuation WX Industry Range
Price/Earnings 26.5x
Price/Sales 4.1x
Price/Book 3.7x
Price/Cash Flow 26.2x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WUXI PHARMATECH CAYMAN-ADR, please visit www.wuxiapptec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.